Literature DB >> 6296313

Specific IgM class antibody production following infection with cytomegalovirus.

H O Kangro, P D Griffiths, T J Huber, R B Heath.   

Abstract

Specific IgM class antibody production was studied in different groups of patients with characterized cytomegalovirus (CMV) infections using a radioimmunoassay (RIA). In pregnant women, IgM antibodies were detected only following primary infection and generally persisted less than 4 months. The demonstration of CMV-specific IgM during pregnancy is therefore diagnostic of recent primary CMV infection. In patients with symptomatic CMV infections, the appearance of IgM antibody was shown to be closely related to the onset of symptoms and coincided with production of complement fixing (CF) antibody. IgM antibodies were at maximum levels 3-4 weeks after presentation but generally declined to low or undetectable levels by 3-4 months. The significance of the results of testing for CMV-specific IgM in relation to clinical and other serological findings in these patients is discussed. IgM antibody production was also demonstrated in renal transplant patients with primary infections and in 6 of 21 recipients with secondary infections. In both groups the antibodies became detectable 3-6 weeks after transplantation but the titres were much higher following primary infection. IgM antibodies persisted throughout follow-up periods of up to 2 years after transplantation in some cases.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6296313     DOI: 10.1002/jmv.1890100306

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Evaluation of a cytomegalovirus glycoprotein B recombinant enzyme immunoassay to discriminate between a recent and a past infection.

Authors:  M J Sipewa; P Goubau; M Bodéus
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 2.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

3.  Screening tests for antibodies to cytomegalovirus: an evaluation of five commercial products.

Authors:  P C Grint; C J Ronalds; H O Kangro; A Campbell-Benzie; F Ward; A E Hardiman; R B Heath
Journal:  J Clin Pathol       Date:  1985-09       Impact factor: 3.411

4.  Immune responses in cardiac transplantation. I. Detection of activated TIa+ cells in the blood during herpes virus infections.

Authors:  C M O'Toole; G S Carvalho; M P Cranage; S Large
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

5.  Immunoglobulin M to cytomegalovirus in primary and reactivation infections in renal transplant recipients.

Authors:  S Chou; D Y Kim; K M Scott; D L Sewell
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

6.  Antibodies to cytomegalovirus in renal allograft recipients: correlation with isolation of virus.

Authors:  J Dolan; J D Briggs; G B Clements
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

7.  The consequences of primary cytomegalovirus infection in pregnancy.

Authors:  P M Preece; J M Blount; J Glover; G M Fletcher; C S Peckham; P D Griffiths
Journal:  Arch Dis Child       Date:  1983-12       Impact factor: 3.791

8.  In situ hybridization for cytomegalovirus DNA in AIDS patients.

Authors:  W C Keh; M A Gerber
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

9.  Clinical evaluation of new automated cytomegalovirus IgM and IgG assays for the Elecsys(®) analyser platform.

Authors:  M G Revello; C Vauloup-Fellous; L Grangeot-Keros; J van Helden; Y Dickstein; I Lipkin; A Mühlbacher; T Lazzarotto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-01       Impact factor: 3.267

10.  EBV VCA IgM and cytomegalovirus IgM dual positivity is a false positive finding related to age and hepatic involvement of primary Epstein-Barr virus infection in children.

Authors:  Min Ji Sohn; Jin Min Cho; Jin Soo Moon; Jae Sung Ko; Hye Ran Yang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.